Edgewise Therapeutics Announces Positive Topline Results From CANYON Phase 2 Trial Of Sevasemten

(RTTNews) - Edgewise Therapeutics, Inc.(EWTX), a muscle disease biopharmaceutical company, announced Monday positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy.

Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies.

The trial met primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to date and the first to achieve its primary endpoint.

As for the key secondary endpoint, sevasemten-treated patients showed stabilization of North Star Ambulatory Assessment (NSAA) with a trend towards improvement at 12 months compared to placebo .

Sevasemten was also well-tolerated and no new safety concerns were observed.